Please login to the form below

Not currently logged in
Email:
Password:

Boehringer acquires Actimis

Boehringer Ingelheim has revealed an acquisition deal potentially worth $515m, that could see it take control of US-based biotechnology company, Actimis
Boehringer Ingelheim has revealed an acquisition deal potentially worth $515m, that could see it take control of US-based biotechnology company, Actimis.

The agreement between the two companies sets out the terms of a structured buyout, which is dependent on the progress of trials of AP768, an asthma compound developed by Actimis. Should the candidate drug, currently in phase I studies, be successful during clinical testing and advance to the phase III stage, Boehringer will take control of 100 per cent of Actimis' shares.

"Actimis' compound provides an innovative addition to Boehringer Ingelheim's portfolio of development candidates for the potential treatment of respiratory disease," said Dr Andreas Barner, vice-chairman of the Board Corporate Division Pharma Research, Development and Medicine at the company.

Dr Peter McWilliams, president and acting CEO of Actimis, said that the scientific team at the company "has done a great job in bringing the programme into the clinic and we are excited to have consummated an agreement with a company possessing the expertise and capabilities of Boehringer."

17th June 2008

Share

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Hive

We're a healthcare communications agency that does things differently. We put patients at the heart of everything we do, while...

Latest intelligence

GDPR and events. What does the pharma industry need to know?
...
Digital trends in B2B sales - how far behind is Pharma?
The modern approach to B2B sales is data-driven, and enabled by digital tools....
The rise of vertical integration in the US payer landscape
Is it a solution to addressing the challenges of the value-based marketplace?...

Infographics